Exploratory Study on the Safety and Efficacy of Disitamab Vedotin in Combination with Anlotinib Hydrochloride for the Treatment of HER-2-expressing Recurrent Platinum-resistant Ovarian Cancer.

Recruiting

Early Phase 1 — Very small initial tests in humans, typically just a few people, to make sure the treatment is safe enough to study further.

Trial locations(1 site)

China

Xiangya Second Hospital of Central South University, Changsha, Hunan